Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Justus Duyster

Showing results (21-30 of 248) with videos related to

Pageof 25
Sort By:
Blood|March 29, 2003
Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptorRebekka Grundler, Christian Thiede, Cornelius Miething, et al.
Cancer|May 28, 2020
Risk of disease recurrence and survival in patients with multiple myeloma: A German Study Group analysis using a conditional survival approach with long-term follow-up of 815 patientsMaximilian Schinke, Gabriele Ihorst, Justus Duyster, et al.
Experimental Hematology|June 28, 2003
Mechanisms of Bcr-Abl-mediated NF-kappaB/Rel activationDieter Kirchner, Justus Duyster, Oliver Ottmann, et al.
The Journal of Biological Chemistry|February 22, 2005
Phosphorylation of grb10 regulates its interaction with 14-3-3Susanne Urschel, Florian Bassermann, Ren-Yuan Bai, et al.
Blood|October 24, 2002
Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase CdeltaIngo Ringshausen, Folker Schneller, Christian Bogner, et al.
Blood|April 15, 2006
Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107)Nikolas von Bubnoff, Paul W Manley, Jurgen Mestan, et al.
Cancer Research|March 26, 2009
FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitroNikolas von Bubnoff, Richard A Engh, Espen Aberg, et al.
International Journal of Hematology|November 22, 2005
Very severe iron-deficiency anemia in a patient with celiac disease and bulimia nervosa: a case reportPhilipp J Jost, Svenja M Stengel, Wolfgang Huber, et al.
British Journal of Haematology|May 27, 2022
Favourable outcomes of double-hit/double-expressor lymphoma and high-grade B-cell lymphoma, not otherwise specified after early dose-intensive treatment and up-front autologous stem cell transplantation: a single-centre retrospective experienceTim Strüßmann, Franziska Glatzki, Monika Engelhardt, et al.
Annals of Hematology|September 24, 2024
15-year remission in refractory FLT3-mutated AML attained by sorafenibChristoph Rummelt, Dietmar Pfeifer, Ralph Wäsch, et al.
Pageof 25

Showing results (21-30 of 248) with videos related to

Sort By:
Pageof 25
Blood|March 29, 2003
Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptorRebekka Grundler, Christian Thiede, Cornelius Miething, et al.
Cancer|May 28, 2020
Risk of disease recurrence and survival in patients with multiple myeloma: A German Study Group analysis using a conditional survival approach with long-term follow-up of 815 patientsMaximilian Schinke, Gabriele Ihorst, Justus Duyster, et al.
Experimental Hematology|June 28, 2003
Mechanisms of Bcr-Abl-mediated NF-kappaB/Rel activationDieter Kirchner, Justus Duyster, Oliver Ottmann, et al.
The Journal of Biological Chemistry|February 22, 2005
Phosphorylation of grb10 regulates its interaction with 14-3-3Susanne Urschel, Florian Bassermann, Ren-Yuan Bai, et al.
Blood|October 24, 2002
Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase CdeltaIngo Ringshausen, Folker Schneller, Christian Bogner, et al.
Blood|April 15, 2006
Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107)Nikolas von Bubnoff, Paul W Manley, Jurgen Mestan, et al.
Cancer Research|March 26, 2009
FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitroNikolas von Bubnoff, Richard A Engh, Espen Aberg, et al.
International Journal of Hematology|November 22, 2005
Very severe iron-deficiency anemia in a patient with celiac disease and bulimia nervosa: a case reportPhilipp J Jost, Svenja M Stengel, Wolfgang Huber, et al.
British Journal of Haematology|May 27, 2022
Favourable outcomes of double-hit/double-expressor lymphoma and high-grade B-cell lymphoma, not otherwise specified after early dose-intensive treatment and up-front autologous stem cell transplantation: a single-centre retrospective experienceTim Strüßmann, Franziska Glatzki, Monika Engelhardt, et al.
Annals of Hematology|September 24, 2024
15-year remission in refractory FLT3-mutated AML attained by sorafenibChristoph Rummelt, Dietmar Pfeifer, Ralph Wäsch, et al.
Pageof 25